HSD17B13 and metabolic dysfunction-associated steatohepatitis: The result showed that the protection of HSD17B13 rs72613567 on NASH and fibrosis might be limited to specific individuals who were aged ≥45 years, women who had class ≥2 obesity or diabetes, and those with PNPLA3 rs738409 CC genotype (Vilar-Gomez et al., 2021).